Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 5 of 5 results for tralokinumab

  1. Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)

    Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.

    Technology appraisal guidance
    Published
    3 August 2022
    View recommendations

    Sections for TA814

  2. Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025]

    In development [GID-TA11349] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

    In development [GID-TA10596] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    In development [GID-TA10597] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

    Discontinued [GID-TA10702]

    Technology appraisal guidance
    Discontinued